We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

CXCL9 and CXCL11 Levels in Patients With Autoimmune Thyroiditis and Habitual Abortions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01644318
Recruitment Status : Unknown
Verified July 2012 by Ankara Education and Research Hospital.
Recruitment status was:  Active, not recruiting
First Posted : July 19, 2012
Last Update Posted : July 19, 2012
Sponsor:
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to measure serum CXCL9 and CXCL11 levels in patients with autoimmune thyroiditis and habitual abortions

Condition or disease
Habitual Abortion

Study Design

Study Type : Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
authoimmıne thyroiditis and habitual abortus
authoimmune thyroiditis
healthy controls


Outcome Measures

Primary Outcome Measures :
  1. Serum CXCL9 and CXCL11 levels in patients with autoimmune thyroiditis and habitual abortions

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Sampling Method:   Probability Sample
Study Population
Endocrinology Outpatient Clinic
Criteria

Inclusion Criteria:

  • non-pregnant women with euthyroid autoimmune thyroiditis and a history of first trimester recurrent spontaneous abortions

Exclusion Criteria:

  • 1) presence of acute or chronic systemic diseases; 2) other autoimmune diseases; 3) pregnancy and lactation over the previous 6 months; 4) evidence of infectious diseases in the last 3 months; 5) treatment with drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs, amiodarone, and lithium; 6) clinical history of hyperthyroidism and/or the presence of anti-TSH receptor antibodies.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01644318


Locations
Turkey
Ankara Education and Research Hospital
Ankara, Turkey, 06340
Sponsors and Collaborators
Ankara Education and Research Hospital
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT01644318     History of Changes
Other Study ID Numbers: 3848
First Posted: July 19, 2012    Key Record Dates
Last Update Posted: July 19, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Abortion, Habitual
Abortion, Spontaneous
Pregnancy Complications